{"ok":true,"trend":{"id":189805,"platform":"news","region":"global","key":"european commission grants marketing authorisation for nezglyal, first pharmacological treatment for cald","title":"European Commission grants marketing authorisation for NEZGLYAL, first pharmacological treatment for cALD","url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNaTlsZm42SDZ3V3VqNS1zc0NVX21TZkNQYnNkY1d2MVhBd0VHanFKem9tYk9PTko3RmZOdWh3Q0FkX0E0LXRrYUN0blpPNXUwRUtLRzdPazZOQ2VkTC1pNkpxdlhVblhtZVZtcVYwZGY5UlJsNEhBcTdySnNBZXVkdmtaZG5fM3M4S05VX3Rfb0VySktqbklSN1h2QlRJNWZLbzlvSGxyZEtuaFA0SHg1ZGdMSmtUQUxVbk1WbEF4SEhHbGgwUktqeWQxN3hVZlF3V1VjaWpUM1lqeVptNHlULW9qOWRpdjJjTjlv?oc=5","first_seen":"2026-09-28T04:16:46.599916Z","last_seen":"2026-09-28T07:00:49.024268Z","last_rank":33,"peak_rank":11,"last_volume":null,"peak_volume":0,"seen_count":3,"score":23.1,"category_hint":"eu_politics","section":"world","category":"eu_politics","summary":"The European Commission has granted marketing authorisation for NEZGLYAL, the first pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD), a rare and severe genetic brain disorder. Until now, treatment options were largely limited to stem cell transplantation and supportive care. The approval offers a new therapy option for patients across the EU and is being noted in rare disease and biotech circles.","why":"It is the first-ever approved medicine for a rare, devastating childhood disease, making it major news in rare disease and EU regulatory circles.","tone":"positive","entities":["European Commission","NEZGLYAL","childhood cerebral adrenoleukodystrophy","European Union"],"summarized_at":"2026-09-28T04:17:06.030945Z","meta":{"via":"scan","lang":"en","term":"european union","source":"BioSpectrum Asia","generic":0.03,"published":"Mon, 28 Sep 2026 03:35:17 GMT"},"nw":0.68,"promo":0.02,"kind":"news_event","importance":1.68,"hidden":false,"hide_reason":null,"judged_at":"2026-09-28T04:16:48.041159Z","title_en":"EU approves NEZGLYAL, first drug for childhood cerebral ALD","section_name":"World","category_name":"EU Politics","timeline":[{"captured_at":"2026-09-28T04:16:46.599916Z","rank":11,"volume":null},{"captured_at":"2026-09-28T05:38:45.735512Z","rank":24,"volume":null},{"captured_at":"2026-09-28T07:00:49.024268Z","rank":33,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNaTlsZm42SDZ3V3VqNS1zc0NVX21TZkNQYnNkY1d2MVhBd0VHanFKem9tYk9PTko3RmZOdWh3Q0FkX0E0LXRrYUN0blpPNXUwRUtLRzdPazZOQ2VkTC1pNkpxdlhVblhtZVZtcVYwZGY5UlJsNEhBcTdySnNBZXVkdmtaZG5fM3M4S05VX3Rfb0VySktqbklSN1h2QlRJNWZLbzlvSGxyZEtuaFA0SHg1ZGdMSmtUQUxVbk1WbEF4SEhHbGgwUktqeWQxN3hVZlF3V1VjaWpUM1lqeVptNHlULW9qOWRpdjJjTjlv?oc=5","author":"BioSpectrum Asia","title":"European Commission grants marketing authorisation for NEZGLYAL, first pharmacological treatment for cALD","snippet":null,"posted_at":"2026-09-28T03:35:17Z","likes":null}],"elsewhere":[],"window":"7d"}}